drugset / Trial / NCT01000857

Repeat Dose Study of Controlled-Release Paroxetine Tablets and Immediate-Release Paroxetine Tablets in Healthy Japanese Male Subjects

NCT01000857

Phase 1 Completed 26 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelOther

Summary

The primary purpose of this study is to compare the steady-state pharmacokinetic profile of paroxetine CR (controlled-release) at the dosage of 25mg/day using the proposed final market tablet of CR 25mg in Japan with that of standard paroxetine IR(immediate-release ) at the dosage of 20mg/day using the currently marketed tablet of IR 20mg in Japan.

Timeline

Start
2009-11-05
Primary completion
2010-02-25
Completion
2010-02-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule 20 mg Oral
Subject Paroxetine Small molecule 25 mg Oral

Indications